Related Experiment Video

Updated: Jul 4, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Taxanes and gene expression in breast cancer cells

Jolanta Rzymowska1, Piotr Maj, Maciej Niemczyk

  • 1Department of Biology and Genetics, Medical University, Lublin, Poland.

Acta Poloniae Pharmaceutica
|June 10, 2008
PubMed

Insights

Paclitaxel treatment for breast carcinoma increased expression of pro-apoptotic, anti-apoptotic, and oncogenes in cells. This indicates paclitaxel influences key cellular pathways even at lower doses.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast carcinoma is a leading cause of cancer-related deaths globally.
  • Paclitaxel is a widely used chemotherapy agent for breast cancer.
  • Understanding the molecular mechanisms of paclitaxel is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To investigate the effects of paclitaxel on gene expression related to apoptosis and oncogenesis in breast carcinoma cells.
  • To determine if lower doses of paclitaxel influence these critical cellular processes.

Main Methods:

  • Gene expression analysis was performed on breast carcinoma cells treated with paclitaxel.
  • A specific low dose of paclitaxel (60 ng/mL) was administered.
  • Expression levels of pro-apoptotic genes, anti-apoptotic genes, caspase genes, and oncogenes were quantified and compared to a control group.

Main Results:

  • Paclitaxel treatment at 60 ng/mL resulted in a statistically significant increase in the expression of pro-apoptotic genes.
  • A significant increase in anti-apoptotic gene expression was also observed.
  • Expression of genes coding for caspases and oncogenes was significantly elevated in paclitaxel-treated cells compared to controls.

Conclusions:

  • Low-dose paclitaxel significantly impacts gene expression involved in both cell death and cell survival pathways in breast carcinoma.
  • The observed increase in oncogene expression warrants further investigation into potential long-term effects or resistance mechanisms.
  • These findings highlight the complex molecular response of breast cancer cells to paclitaxel, even at sub-therapeutic concentrations.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.